For the year ending 2025-12-31, PVCT had -$238,435 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -5,505,124 |
| Stock-based compensation | 1,237,546 |
| Non-cash operating lease expense | 48,128 |
| Depreciation | 1,863 |
| Prepaid expenses and other current assets | -478,387 |
| Accounts payable | -390,331 |
| Unearned grant revenue | -336,108 |
| Accrued interest | 201,772 |
| Other accrued expenses | 986,003 |
| Operating lease liability | -48,127 |
| Net cash used in operating activities | -3,325,991 |
| Proceeds from issuance of convertible notes payable | 870,000 |
| Proceeds from issuance of convertible notes payable - related parties | 1,640,000 |
| Proceeds from issuance of common stock of majority-owned subsidiary | 850,000 |
| Repayment of short-term note payable | 272,994 |
| Net cash provided by financing activities | 3,087,006 |
| Effect of exchange rates on cash and restricted cash | 550 |
| Net decrease in cash and restricted cash | -238,435 |
| Cash and restricted cash, beginning of period | 489,726 |
| Cash and restricted cash, end of period | 251,291 |
| Cash | 251,291 |
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)